Journal Mobile Options
Table of Contents
Vol. 72, No. 4, 2000
Issue release date: October 2000
Neuroendocrinology 2000;72:195–198
(DOI:10.1159/000054587)

Reduced Leptin Levels in Human Narcolepsy

Schuld A. · Blum W.F. · Uhr M. · Haack M. · Kraus T. · Holsboer F. · Pollmächer T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Recently, hypocretins have been implicated in the pathophysiology of narcolepsy, a sleep disorder characterized particularly by the occurrence of excessive daytime sleepiness and cataplexy. Hypocretins, which stimulate food intake, have been reported to be absent in the cerebrospinal fluid (CSF) of the majority of patients suffering from narcolepsy. Because these patients also display an increased body mass index (BMI), it has been suggested that disturbances in metabolism and food intake regulation may be present. To further investigate these presumed alterations, we studied the production of leptin, a fat-cell-derived hormone signaling to the brain the size of the adipose tissue. We measured the levels of leptin in serum and CSF from 15 narcoleptic patients and compared the results to those from age-, sex- and BMI-matched control groups of depressive patients and patients suffering from a noninflammatory neurological disorder. Compared to both control groups, leptin levels in serum, but not in the CSF, were significantly reduced in narcoleptic patients by more than 50%. These results support the hypothesis that human narcolepsy is accompanied by complex alterations of the regulation of food intake and metabolism. The significance of these alterations for the core symptomatology of narcolepsy should be a target of future research.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Aldrich MS: Narcolepsy. N Engl J Med 1990;323:389–394.
  2. Mignot E, Tafti M, Dement WC, Grumet FC: Narcolepsy and immunity. Adv Neuroimmunol 1995;5:23–37.
  3. Hinze-Selch D, Wetter TC, Zhang Y, Lu HC, Albert ED, Mullington J, Wekerle H, Holsboer F, Pollmächer T: In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998;50:1149–1152.
  4. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365–376.
  5. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M: Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999;98:437–451.
  6. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39–40.
  7. Sakurai T: Orexins and orexin receptors: Implication in feeding behavior. Regul Pept 1999;85:25–30.
  8. Siegel JM: Narcolepsy: A key role for hypocretins (orexins). Cell 1999;98:409–412.
  9. Schuld A, Hebebrand J, Geller F, Pollmächer T: Increased body-mass index in patients with narcolepsy. Lancet 2000;355:1274–1275.
  10. Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Muller J, Skakkebaek NE, Heiman ML, Birkett M, Attanasio AM, Kiess W, Rascher W: Plasma leptin levels in healthy children and adolescents – Dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metabol 1997;82:2904–2910.
  11. Yamamoto Y, Ueta Y, Date Y, Nakazato M, Hara Y, Serino R, Nomura M, Shibuya I, Matsukura S, Yamashita H: Down regulation of the prepro-orexin gene expression in genetically obese mice. Brain Res Mol Brain Res 1999;65:14–22.
  12. Herpertz S, Wagner R, Albers N, Blum WF, Pelz B, Langkafel M, Kopp W, Henning A, Oberste-Berghaus C, Mann K, Senf W, Hebebrand J: Circadian plasma leptin levels in patients with anorexia nervosa: Relation to insulin and cortisol. Horm Res 1998;50:197–204.
  13. Sinton CM, Fitch TE, Gershenfeld HK: The effects of leptin an REM sleep and slow wave delta in rats are reversed by food deprivation. J Sleep Res 1999;8:197–203.
  14. Piper DC, Upton N, Smith MI, Hunter AJ: The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000;12:726–730.
  15. Pollmächer T, Mullington J, Lauer CJ: REM sleep disinhibition at sleep onset: A comparison between narcolepsy and depression. Biol Psychiatry 1997;42:713–720.
  16. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991–997.
  17. Kilduff TS, Peyron C: The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 2000;23:359–365.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00